{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-001524","form_type":"8-K","ticker":"COLL","cik":"0001267565","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.639842+00:00","generated_at":"2026-06-05T18:28:23.114274+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Collegium Pharma reports record Q4/FY2023 revenue; GAAP net income of $31.9M Q4, $48.2M FY","bullets":["Record Q4 revenue $149.7M (+16% YoY); FY revenue $566.8M (+22% YoY).","GAAP net income $31.9M Q4 ($0.82 diluted) vs loss of $7.2M in Q4 2022; FY net income $48.2M.","Record adjusted EBITDA $104.2M Q4, $367.0M FY (+38% YoY each).","Repurchased $75M shares in 2023; new $150M buyback authorized Jan 2024.","FY 2024 guidance: product revenue $580–595M, adjusted EBITDA $380–395M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-001524","json":"https://secwatch.observer/filing/0001558370-24-001524.json","markdown":"https://secwatch.observer/filing/0001558370-24-001524.md","text":"https://secwatch.observer/filing/0001558370-24-001524.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267565/000155837024001524/0001558370-24-001524-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267565/000155837024001524/coll-20240222x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T18:28:23.114274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"41c913d3bca21d8a7fa36bea1d0506ff9731e9e3","claim":"COLLEGIUM PHARMACEUTICAL, INC reported the quarterly period and fiscal year ended December 31, 2023 results: revenue $149.7 Million and $566.8 Million, net income $31.9 Million and $48.2 Million, EPS $0.99 GAAP earnings per share (basic) and $0.82 GAAP earnings per share (diluted); $1.43 GAAP earnings per share (basic). Guidance reaffirmed.","evidence_excerpt":"8-K. ​ --- EX-99.1 (EX-99.1) --- ​ Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results ​ – Generated Record Quarterly and Full-Year Net Revenue of $149.7 Million and $566.8 Million – ​ – Achieved Quarterly and Full-Year GAAP Net Income of $31.9 Million and $48.2 Million – ​ – Delivered Record Quarterly and Full-Year Adjusted EBITDA of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000155837024001524/0001558370-24-001524-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarterly period and fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$149.7 Million and $566.8 Million"},{"label":"Net income","value":"$31.9 Million and $48.2 Million"},{"label":"EPS","value":"$0.99 GAAP earnings per share (basic) and $0.82 GAAP earnings per share (diluted); $1.43 GAAP earnings per share (basic)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}